Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update

Vir Biotechnology, Inc. (VIR) announced an update on their ongoing clinical study.

The phase 2 study “A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection” aims to test new drug combinations for long-term control of chronic hepatitis B. It focuses on safety, how well patients tolerate treatment, and early signs that these drugs could move the market toward more functional cures.

The study tests three injected drugs: VIR-2218 (elebsiran), VIR-3434 (tobevibart), and PEG-IFNα. They are designed to work together to lower virus levels and boost the immune response, with the goal of reducing or replacing long-term daily oral therapy.

The trial is an interventional study, meaning participants receive active treatment rather than observation only. It uses a non-randomized, parallel group design with no blinding, so different cohorts get set regimens and all parties know which regimen is given, keeping the focus on treatment effect and safety in real-world style use.

Multiple experimental cohorts receive different dosing durations and combinations, from short 4-week courses to 44-week regimens. This structure allows Vir Biotechnology, Inc. to compare how single agents and combinations perform over time, and to decide which regimens are worth advancing into larger pivotal trials.

The study was first submitted on April 21, 2021, signaling the formal start of Vir’s mid-stage push in hepatitis B. The trial has now reached “Completed” status, with the latest update filed on April 21, 2026, marking an important transition point as the company reviews full data and plans the next phase of development.

While primary completion and final data lock dates are not listed, the completed status suggests all main outcomes have been collected. Investors should watch for peer-reviewed data, conference presentations, or company updates that translate this clinical milestone into clear development timelines and potential regulatory strategies.

For Vir (VIR), a strong phase 2 readout in chronic hepatitis B could support a re-rating of the stock, especially if data suggest durable responses that rival or improve on today’s standard oral antivirals. Weak or inconclusive results, by contrast, could pressure the shares and shift attention toward other assets in the pipeline.

The competitive field includes companies such as Gilead, Johnson & Johnson, and smaller biotech peers all pursuing finite or curative hepatitis B regimens. Any sign that VIR-2218 and VIR-3434 combinations offer better depth or durability of response could differentiate Vir’s platform and enhance partnering or acquisition interest.

In the near term, sentiment will depend on how clearly Vir communicates efficacy, safety, and the path to phase 3 after this completed study update. The trial status and recent filing confirm that the program remains active and updated, with further details available on the ClinicalTrials portal under NCT04856085.

To learn more about VIR’s potential, visit the Vir Biotechnology, Inc. drug pipeline page.